- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 02.07. | Insilico Medicine, Takeda partner on AI-driven drug discovery | ||
| 02.07. | Inocras, AimedBio team up for cancer treatments | ||
| 01.07. | QuantumCell commits $2.2bn on AlzeCure's Alzheimer's platform | ||
| 01.07. | Sanofi aims for Nexviazyme approval in younger Pompe disease patients | ||
| 01.07. | Anthropic debuts AI-driven pharma R&D tool, Claude Science | ||
| 01.07. | Medical journal retracts Tavneos pivotal paper amid wider regulatory clampdown | ||
| 01.07. | US FDA rejects approval of Unicycive's kidney disease therapy | ||
| 01.07. | Eli Lilly and Innovent agree Verzenios commercialisation deal in China | ||
| 30.06. | Lilly and Regeneron amongst first incumbents to FDA's fast-track facility scheme | ||
| 30.06. | Talawar Therapeutics to debut on Nasdaq with $285m as Dupixent challenger | ||
| 30.06. | Anixa Biosciences secures Korean patent for breast cancer vaccine | ||
| 30.06. | Zymeworks agrees to buy Theravance Biopharma for $929m | ||
| 29.06. | EMA backs market rollback of rare disease drug Tavneos over data concerns | ||
| 29.06. | Biogen trims Apellis pipeline and R&D team after $5.6bn takeover | ||
| 29.06. | FDA issues complete response letter to Sobi's NASP for gout | ||
| 29.06. | Lilly's Jaypirca receives CHMP positive opinion for CLL in Europe | ||
| 26.06. | Immunai and Boehringer partner to identify T-cell targets | ||
| 26.06. | Tryngolza charts blockbuster course after FDA's hypertriglyceridemia approval | ||
| 26.06. | Lilly-backed Absci banks $100m to progress endometriosis, hair loss therapy | ||
| 26.06. | Ionis grants Recordati rights to zilganersen for Alexander disease | ||
| 26.06. | BIO 2026: Former FDA staff question agency's "radical transparency" approach | ||
| 25.06. | Merck KGaA to buy Bio-Techne for $11.3bn in life science footprint expansion | ||
| 25.06. | MSD's Keytruda-Padcev combo secures EC approval for MIBC | ||
| 25.06. | RQ Bio secures $115m to develop influenza antibody programme | ||
| 25.06. | BIO 2026: How NIH cuts have threatened US competitiveness against China |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.